AI in Pharma Market

Artificial Intelligence (AI) in pharma is defined as system of interrelated and automated technologies in the biotech industry which can work autonomously, without any human intervention. AI is an evolving technology which is being used in various facets of the pharma sector, from drug development to diagnosis as well as patient care. Artificial intelligence use in pharmaceutical technology has been increasing recently. Thus, the use of technology can save time and money, while offering a far better understanding of the relationships among various formulations and processes parameters. The rising number of cross-industry collaboration and partnerships, coupled with the increasing need to reduce drug discovery & development costs, are the two major factors which are responsible for the growth of global artificial intelligence in pharma market. In addition, the rising adoption of cloud-based applications and services and the imminent patent expiry of successful drugs are further propelling the growth of the AI in pharma market. Furthermore, the rising adoption of artificial intelligence (AI) for clinical trials research is also accelerating its demand for AI in the pharma market. To bring a novel drug to the market it takes on an average approximately 10-15 years moreover, half of the time is consumed in the clinical trial phases of the drug development cycle. Therefore, using artificial intelligence models and analytics tools can propel the clinical trial phases, interpretation of diseases, recognize suitable cases and key investigators to inform site selection and help novel clinical study designs. Additionally, the rising volume of monumental data produced by the molecule screening processes and the preclinical studies is further increasing the adoption of artificial intelligence in the pharma space. A huge volume of data makes the analysis of the scientific literature a complicated process. Hence, scientists use artificial intelligence to fuel the screening process and reduce the time required for studying and identifying drug molecule interactions and histology data. On the other hand, the factors such as dearth of skilled expertise and inadequate availability of databases are the likely to hamper the AI in pharma market.

Moreover, the increasing adoption of AI in the drug delivery space to perform the standard processes such as data mining and customization capabilities of the AI platforms is opening new avenues for the growth of the AI in pharma market. The AI algorithm-based models offer precise analysis of human physiology response compared to animal models. In addition to this, AI-based models also help in reducing the experimental costs and efficient prediction of cross-species differences.

The global AI in Pharma Market is segregated on the basis of Technology as Context-Aware Processing, Natural Language Processing, Querying Method and Deep Learning. Based on Drug Type the global AI in Pharma Market is segmented in Small Molecule and Large Molecules. Based on Application the global AI in Pharma Market is segmented in Diagnosis, Clinical Trial Research, Drug Discovery, Research and Development and Epidemic Prediction.

The global AI in Pharma Market report provides geographic analysis covering regions, such as Europe, North America, Asia Pacific, and Rest of The World. The AI in Pharma Market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.

Competitive Analysis

Novartis, IBM Watson, Microsoft Corporation, Merck, GNS Healthcare and others are among the major players in the global AI in Pharma Market. The companies studied in terms of product strategy and various n several growth and expansion strategies to gain a competitive edge in the market. The major players not only follow value chain integration with business operations in multiple stages of the value chain.

• In November 2018, Cyclica, a Canadian-biotechnology company which deploys AI and computational biophysics to decentralize drug discovery has partnered with Bayer for drug discovery programs. These companies will enhance drug discovery applications by rising artificial intelligence into the polypharmacological outlines of small molecules while further developing Cyclica's integrated system of licensing technologies.
• In January 2020, Pfizer, an American pharmaceutical company, collaborated with a biotech startup Insilico Medicine to recognize drug targets. With artificial intelligence tools Pfizer can accelerate drug discovery and minimize drug development costs in the drug development processes.

The global AI in Pharma Market has been segmented as below:

AI in Pharma Market, By Technology

• Context-Aware Processing
• Natural Language Processing
• Querying Method
• Deep Learning

AI in Pharma Market, By Drug Type

• Small Molecule
• Large Molecules

AI in Pharma Market, By Application

• Diagnosis
• Clinical Trial Research
• Drug Discovery
• Research and Development
• Epidemic Prediction

AI in Pharma Market, By Region

• Europe
• North America
• Asia Pacific
• Rest of The World

AI in Pharma Market, By Company

• Novartis
• IBM Watson
• Microsoft Corporation
• Merck
• GNS Healthcare
• Google
• AstraZeneca
• Atomwise Inc.
• Exscientia
• Cyclica
• NVIDIA Corporation
• XtalPi Inc.
• BenevolentAI
• Cloud Pharmaceuticals Inc
• BERG LLC
• Bayer
• Pfizer
• Recursion Pharmaceuticals Inc.
• Bristol-Myers Squibb

The report covers the below scope:

• Global AI in Pharma Market sizes from 2020 to 2026, along with CAGR for 2020-2026
• Market size comparison for 2019 vs 2026, with actual data for 2019, estimates for 2019 and forecast from 2020 to 2026
• Global AI in Pharma Market trends, covering comprehensive range of consumer trends & manufacturer trends
• Value chain analysis covering participants from raw material suppliers to the downstream buyer in the global AI in Pharma Market
• Major market opportunities and challenges in forecast timeframe to be focused
• Competitive landscape with analysis on competition pattern, portfolio comparisons, development trends and strategic management
• Comprehensive company profiles of the key industry players

The years considered for the study are as follows:

• Base year - 2019
• Estimated year - 2019
• Projected year - 2020
• Forecast period - 2021 to 2026

Report Scope:

The global AI in Pharma Market report scope includes detailed study covering underlying factors influencing the industry trends. The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies. The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global AI in Pharma Market share. Major industry players with significant revenue share include Novartis, IBM Watson, Microsoft Corporation, Merck, GNS Healthcare and others.

Why to Buy this Report:

• Gain detailed insights on the AI in Pharma industry trends
• Find complete analysis on the market status
• Identify the AI in Pharma Market opportunities and growth segments
• Analyse competitive dynamics by evaluating business segments & product portfolios
• Facilitate strategy planning and industry dynamics to enhance decision making

Target Audience:

• The report targeted towards the existing players in the industry is as follows:
• Market Manufacturers/Service Providers
• Market Wholesale/Traders
• Investment and Financial Institutions

Free and Paid Customization based on the requirement

 

1.      Introduction

1.1.       Key Points

1.2.      Report Description

1.3.      Markets Covered

1.4.      Stakeholders

2.     Research Methodology

2.1.      Research Scope

2.2.     Research Methodology

2.2.1.     Market Research Process

2.2.2.    Research Methodology

2.2.2.1.           Secondary Research

2.2.2.2.          Primary Research

2.2.2.3.          Models for Estimation

2.3.     Market Size Estimation

2.3.1.     Bottom-Up Approach

2.3.2.    Top-Down Approach

3.     Executive Summary

4.    Market Overview

4.1.      Introduction

4.2.     Drivers

4.3.     Restraints

4.4.     Opportunities

4.5.     Challenges

5.     AI in Pharma Market, By Technology

5.1.      Key Points

5.2.  Context-Aware Processing

5.3.  Natural Language Processing

5.4.  Querying Method

5.5.  Deep Learning

6.    AI in Pharma Market, By Drug Type

6.1.      Key Points

6.2. Small Molecule

6.3. Large Molecules

7.     AI in Pharma Market, By Application

7.1.      Key Points

7.2.  Diagnosis

7.3.  Clinical Trial Research

7.4.  Drug Discovery

7.5.  Research and Development

7.6.  Epidemic Prediction

8.    Competitive Landscape

8.1.      Introduction

8.2.     Start-up companies- AI in Pharma Market

8.3.     Recent Developments

8.3.1.     Mergers & Acquisitions

8.3.2.    New Product Developments

8.3.3.    Portfolio/Production Capacity Expansions

8.3.4.    Joint Ventures, Collaborations, Partnerships & Agreements

8.3.5.    Others

9.    Company Profile

9.1.  Novartis

9.2. IBM Watson

9.3. Microsoft Corporation

9.4. Merck

9.5.  GNS Healthcare

9.6. Google

9.7.  AstraZeneca

9.8. Atomwise Inc.

9.9. Exscientia

9.10.                   Cyclica

9.11.                     NVIDIA Corporation

9.12.                   XtalPi Inc.

9.13.                    BenevolentAI

9.14.                   Cloud Pharmaceuticals Inc

9.15.                    BERG LLC

9.16.                   Bayer

9.17.                    Pfizer

9.18.                   Recursion Pharmaceuticals Inc.

9.19.                   Bristol-Myers Squibb